ALung was recently given the ok by an independent Data and Safety Monitoring board in the U.S. to continue its clinical trial, UPMC announced the launch of a new telemedicine company aimed at treating infectious diseases remotely, and Oscar Health signed on with Cavulus to help launch its Medicare Advantage Programs. Get a closer look at each – and more – in this month’s Portfolio Spotlight.
ALung was recently awarded approval from an independent Data and Safety Monitoring board to continue its U.S.-based VENT-AVOID clinical trial. This approval, without modification, is a significant milestone for the company as it gets closer to its goal of providing a new tool to treat acute respiratory failure.
Oscar Health is the latest company to choose Cavulus to expand its reach in the Medicare Advantage space. Through the entire suite of cloud-based software, Oscar Health will be able to streamline member acquisition and enrollment management, and benefit from solutions for marketing, sales management, and administrative tasks.
Health Catalyst was recently featured in RevCycle Intelligence for the work it has done with Allina Health. The piece explains how the health system saw a $2 million patient collections boost after implementing a propensity-to-pay model with the help of Health Catalyst.
Infectious Disease Connect was highlighted in a number or major publications, including MedCity News, Modern Healthcare, and HIT Consultant. Several of the stories focused on how the company was formed – a result of the success of UPMC’s tele-infectious disease program that was launched in 2013. The company will now be able to connect patients and physicians at rural community hospitals with infectious disease specialists at UPMC.
